Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Pituitary Disorders
•
Adrenal Disorders
How do you approach monitoring for autoimmune disorders in patients with surgical remission of Cushing’s disease, given the higher incidence of autoimmune disease in this population?
PMID:
38373302
Related Questions
What is the likelihood of recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients who develop immunotherapy induced adrenal insufficiency?
Does growth hormone (GH) replacement therapy reduce the risk of fractures in patients with GH deficiency?
Should we be aiming for normalization of both late-night salivary cortisol and 24hr urinary free cortisol levels when monitoring response to Cushing's disease treatment?
When do you check macroprolactin in the evaluation of hyperprolactinemia?
Can 24-hour urine aldosterone levels be used to screen for primary aldosteronism in a patient taking finerenone?
When do you recommend using L-arginine stimulated copeptin testing to evaluate for central diabetes insipidus (AVP-deficiency)?
What factors guide you in adjusting the dose of fludrocortisone in a patient with primary adrenal insufficiency?
Should we be considering transsphenoidal surgical resection as first-line therapy for prolactinomas?
Given the new 2022 WHO classification of pituitary tumors, should we be regularly counseling our patients about the risk of malignancy for what we previously referred to as pituitary adenomas but now classified as pituitary neuroendocrine tumors (PitNETs)?
When do you consider using setmelanotide for treatment of hypothalamic obesity?
